Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Yale Researcher Says Whooping Cough Vaccines Effective, Despite Outbreaks

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
Dr. Shapiro’s editorial was published in the Nov. 28 issue of Journal of the American Medical Association.

Despite recent outbreaks of pertussis (whooping cough) - a highly contagious bacterial disease that is preventable by the current pertussis vaccines - Yale researcher Dr. Eugene Shapiro maintains in an editorial that the vaccines are effective and should still be administered.

Shapiro said that although acellular vaccines may be suboptimal, they are still quite effective and should be focused on pregnant women, infants, and caregivers.

“It is most important to try to protect infants, who have the most severe illnesses and highest mortality from pertussis,” said Shapiro, professor of pediatrics.

Shapiro continued, “The highest rates of both hospitalizations and deaths from pertussis occurred in children younger than two months.”

The resurgence of pertussis in the United States, even among those who have been vaccinated in the past, has led many experts to question the long-term duration of immunity.

Published in the Nov. 28 issue of Journal of the American Medical Association (JAMA), Shapiro’s editorial stresses that while there is speculation that the outbreak is linked to the vaccine’s waning immunity over time, there is no definitive evidence that this is the primary or sole reason for increases in reported cases of pertussis.

The original whole-cell pertussis vaccine DTwP, which also included vaccines against diphtheria and tetanus, was introduced for childhood immunization in the 1940s.

But acellular combination pertussis vaccines (DTaP) replaced DTwP in the early 1990s because the whole-cell vaccine had high rates of side-effects such as fever and inflammation at the injection site.

DTaP uses purified components to reduce side-effects, but Shapiro said there is not enough data on the duration of the DTaP vaccine’s immunity.

“There have been periodic outbreaks in the past even with the whole cell vaccine, so there is no way to know for sure that the outbreaks are linked to the accelular vaccine,” he said. “There is no definitive evidence as to why there are increased outbreaks, and there may be multiple reasons for it.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Wednesday, July 08, 2015
Racial and Economic Gap in Awareness of Lifesaving HPV Vaccine
Research finds worrisome racial, economic, educational, and gender gaps in awareness about the lifesaving vaccine for HPV.
Monday, June 10, 2013
Yale Researchers Trick Bacteria to Deliver a Safer Vaccine
Yale researchers have developed a new trick, using bacteria’s own cellular mistakes to deliver a safe vaccine.
Tuesday, March 19, 2013
Pioneering Yale Immunologist Receives Inaugural NIH Award
Renowned Yale immunologist Ruslan Medzhitov has been awarded the inaugural Lurie Prize in the Biomedical Sciences from the Foundation for the National Institutes of Health (FNIH).
Thursday, February 28, 2013
For Drug Makers, New 3-D Control Opens Wealth of Options
Scientists have demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.
Monday, February 18, 2013
Yale Scientists Find a Way to Make Disease-Causing Proteins Vulnerable to Drugs
Researchers have identified a novel way to design drugs for previously inaccessible proteins.
Friday, July 27, 2012
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos